PMID- 21346353
OWN - NLM
STAT- MEDLINE
DCOM- 20110728
LR  - 20161125
IS  - 1421-9794 (Electronic)
IS  - 0009-3157 (Linking)
VI  - 57
IP  - 1
DP  - 2011
TI  - Helicobacter pylori therapy in children: a focus on proton pump inhibitors.
PG  - 85-93
LID - 10.1159/000323619 [doi]
AB  - Over the last two decades, there have been many studies on children who have 
      sought an effective and safe treatment to eradicate Helicobacter pylori 
      infection, but as yet, no therapy regimen has been found which is always 
      effective and safe. Differences in drug response among pediatric patients are 
      common. Such individual variability in drug response is multifactorial, including 
      environmental, genetic, development and disease determinants that affect the 
      disposition of a given drug. In pediatric efficacy studies for the management of 
      H. pylori eradication in children, the most commonly tested regimen has contained 
      a combination of proton pump inhibitor (PPI), clarithromycin and amoxicillin, 
      followed by triple therapies containing PPI, clarithromycin and nitroimidazoles. 
      Thus, PPIs are an integral part of triple therapy for H. pylori eradication in 
      children with gastroduodenal disease. In this article, we comprehensively review, 
      from a pediatric point of view, the literature on the clinical, pharmacologic and 
      microbiologic properties of PPIs. We also discuss genetic, developmental and 
      other host-related factors that may affect the efficacy of these drugs. Finally, 
      we provide some guidance regarding their potential role and limitations for H. 
      pylori eradication in children.
CI  - Copyright (c) 2011 S. Karger AG, Basel.
FAU - Chiesa, Claudio
AU  - Chiesa C
AD  - Institute of Molecular Medicine, National Research Council, Rome, Italy. 
      claudio.chiesa@artov.inmm.cnr.it
FAU - Anania, Caterina
AU  - Anania C
FAU - Pacifico, Lucia
AU  - Pacifico L
FAU - Olivero, Giuseppe
AU  - Olivero G
FAU - Osborn, John F
AU  - Osborn JF
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110223
PL  - Switzerland
TA  - Chemotherapy
JT  - Chemotherapy
JID - 0144731
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
SB  - IM
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Aryl Hydrocarbon Hydroxylases/genetics
MH  - Child
MH  - Cytochrome P-450 CYP2C19
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Polymorphism, Genetic
MH  - Proton Pump Inhibitors/pharmacology/*therapeutic use
EDAT- 2011/02/25 06:00
MHDA- 2011/07/29 06:00
CRDT- 2011/02/25 06:00
PHST- 2010/02/16 00:00 [received]
PHST- 2010/08/07 00:00 [accepted]
PHST- 2011/02/25 06:00 [entrez]
PHST- 2011/02/25 06:00 [pubmed]
PHST- 2011/07/29 06:00 [medline]
AID - 000323619 [pii]
AID - 10.1159/000323619 [doi]
PST - ppublish
SO  - Chemotherapy. 2011;57(1):85-93. doi: 10.1159/000323619. Epub 2011 Feb 23.